Medical Condition News

RSS

Covidien granted FDA 510(k) clearance for Kendall SCD Sleeve and Kendall SCD 700 Series Controller

Covidien, a leading global provider of healthcare products and recognized innovator in intermittent pneumatic compression (IPC), today announced 510(k) clearance from the U.S. Food and Drug Administration for the Kendall SCD™ Sequential Compression Comfort Sleeve and Kendall SCD™ 700 Series Controller. The new system will be launched next month in the U.S. and will deliver an improved level of comfort for patients, while reducing the risk of venous thromboembolism (VTE).

4 Nov 2010

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.

4 Nov 2010

CaPre drug candidate effective in managing impaired glucose tolerance

Neptune Technologies & Bioressources Inc. subsidiary Acasti Pharma Inc. reports preclinical results showing that its leading drug candidate CaPre, performed significantly better than the currently marketed drug, Lovaza, at managing impaired glucose tolerance (IGT) a serious pre-diabetic state associated with increased risk of diabetes and heart disease.

4 Nov 2010

Stereotaxis receives $1.5 million in grants under QTDP program

Stereotaxis, Inc. announced today that it has been awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program that was enacted under the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

Undamaged portions of brain 'take over' and support recovery of function: Study

New research provides fascinating insight into mechanisms that underlie recovery after damage to a region of the brain important for memory and attention. The research, published by Cell Press in the November 4th issue of the journal Neuron, highlights the role of undamaged portions of the brain that can "take over" and support the recovery of function.

4 Nov 2010

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.

4 Nov 2010

CombiMatrix receives $488,958 grant under QTDP program

CombiMatrix Corporation a molecular diagnostics company with a focus on DNA-based clinical diagnostic testing services for oncology and pre-and postnatal developmental disorders, announced today the award of $488,958 under the Internal Revenue Service's Section 48D for Qualifying Therapeutic Discovery Projects.

4 Nov 2010

'Phantom' images brain keeps for visual comparisons stored in brain's neural network

Brain research over the past 30 years has shown that if a part of the brain controlling movement or sensation or language is lost because of a stroke or injury, other parts of the brain can take over the lost function - often as well as the region that was lost.

4 Nov 2010

Volunteering benefits older adults with functional limitations

Volunteering is known to provide health benefits to the person doing the volunteering. Now, a new study finds that older adults with functional limitations (trouble conducting daily tasks like cooking meals) in particular appear to reap the benefits from helping others.

4 Nov 2010

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe. This market will continue to grow as physicians increasingly use the technology in cases where other devices may not be suitable.

4 Nov 2010

Kidney disease registry could help clinicians to evaluate treatment strategies for CKD patients

A registry of health care information on patients with mild to moderate chronic kidney disease (CKD) could help physicians improve care for affected individuals, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that officials could use such a registry to develop a national surveillance system to identify and track various aspects of CKD.

4 Nov 2010

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues and organs, today announced that OXY111A, its clinical stage candidate for the treatment of chronic heart failure and cancer, has been selected as one of Windover's "Top 10 Cardiovascular/Metabolic Projects to Watch."

4 Nov 2010

Patient share of Actemra for RA to exceed patient share for Cimzia and Simponi, says Report

Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.

4 Nov 2010

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that data from a phase I single-agent clinical trial of brentuximab vedotin (SGN-35) will be published in the November 4, 2010 issue of the New England Journal of Medicine.

4 Nov 2010

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Removal of the prostate gland often eradicates early-stage cancer. But patients whose cancer has spread may need to follow up with what is known as salvage radiation therapy. Researchers at Fox Chase have now determined a better way to monitor outcomes after this procedure.

4 Nov 2010

Frequent long-term use of cell phones may increase cancer risk

Public health concerns have been raised today about the safety of being exposed to radiofrequency (RF) radiation emitted from cell phones. A report released by the Ontario Agency for Health Protection and Promotion (OAHPP) in September 2010 was one of the studies cited as providing evidence that frequent long-term use of cell phones may be associated with an increased risk of cancer.

4 Nov 2010

Early interference in entorhinal cortex may halt progression of Alzheimer's disease

New research is helping to unravel the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain. The research, published by Cell Press in the November 4th issue of the journal Neuron, follows disease progression from a vulnerable brain region that is affected early in the disease to interconnected brain regions that are affected in later stages. The findings may contribute to design of therapeutic interventions as targeting the brain region where AD originates would be simpler than targeting multiple brain areas.

4 Nov 2010

Scientists identify events that causes AD progression

Scientists at the Gladstone Institute of Neurological Disease (GIND) have offered new information about the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain.

4 Nov 2010

Gender-related disparity in outcomes of lower extremities peripheral arterial disease continues: Study

Researchers from the Mount Sinai School of Medicine report that despite overall improvement, there is still gender-related disparity in outcomes of lower extremities peripheral arterial disease (PAD). Details of their study appear in the November issue of the Journal of Vascular Surgery®, published by the Society for Vascular Surgery®.

4 Nov 2010

Medical Condition News

Covidien granted FDA 510(k) clearance for Kendall SCD Sleeve and Kendall SCD 700 Series Controller

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

CaPre drug candidate effective in managing impaired glucose tolerance

Stereotaxis receives $1.5 million in grants under QTDP program

Undamaged portions of brain 'take over' and support recovery of function: Study

NWBT receives $490,000 in two grants under QTDP program

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

CombiMatrix receives $488,958 grant under QTDP program

'Phantom' images brain keeps for visual comparisons stored in brain's neural network

Volunteering benefits older adults with functional limitations

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

Kidney disease registry could help clinicians to evaluate treatment strategies for CKD patients

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

Patient share of Actemra for RA to exceed patient share for Cimzia and Simponi, says Report

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Frequent long-term use of cell phones may increase cancer risk

Early interference in entorhinal cortex may halt progression of Alzheimer's disease

Scientists identify events that causes AD progression

Gender-related disparity in outcomes of lower extremities peripheral arterial disease continues: Study

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News